---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-22-000034"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:20:51.299637+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Sema4 announces non-reliance on previously issued financial statements and reports Q4 2021 results

## Summary
- Non-reliance on previously issued financial statements for years ended Dec 31, 2020 and 2019 due to expense classification errors in cost of services and selling & marketing.
- Identified adjustments in cost of services recognition for Q1-Q3 2021; restated financials to be included in 2021 10-K filed March 14, 2022.
- Q4 2021 test volumes (ex-COVID) up 37% YoY; total revenue $57.8M, net loss $40.2M vs $125.7M loss in prior year.
- Full year 2021 revenue $212.2M up from $179.3M; net loss $245.4M vs $241.3M.
- Reiterates FY2022 revenue guidance $215-225M; expects to close GeneDx acquisition by end of Q2 2022.

## SEC filing metadata
- accession: 0001818331-22-000034
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000034/0001818331-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000034/smfr-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-22-000034
- JSON: https://secwatch.observer/filing/0001818331-22-000034.json
- Plain text: https://secwatch.observer/filing/0001818331-22-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.